SANGAMO THERAPEUTICS, INC (SGMO) Form 8-K — May 14, 2026
Sangamo Therapeutics reported a Q1 2026 net loss of $31.0 million and revenue of $1.4 million, driven by the expiration of a Pfizer sublicense and reduced license fees. The company holds only $27.6 million in cash, which management estimates will fund operations only into the third quarter of 2026. The filing highlights severe liquidity risk, stating that the company’s ability to continue as a going concern is dependent on securing substantial additional funding. Management warned that failure to secure a significant partnership or financing could force the company to cease operations, liquidate assets, or seek bankruptcy protection in the very near term.
Key figures
- Revenue
- 1442000
- Guidance
- GAAP operating expenses $110M-$130M in 2026; Non-GAAP operating expenses $100M-$120M in 2026. Cash sufficient into Q3 2026.
- Total Assets
- 59965000
- Cash Position
- 27586000
- Q1 2025 revenue
- 6437000
- Shares outstanding
- 389616000
- Gaap operating expenses q1
- 33388000
- Non gaap operating expenses q1
- 31700000
Price after filing
Close on the filing date to close N calendar days later (from $0.14). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.